VAUGHAN, Ontario / Jan 22, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2024 financial results on Wednesday, February 19, 2025. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call.
Conference Call Details
Date: | Wednesday, February 19, 2025 | |||||
Time: | 8 a.m. ET | |||||
Webcast: | ||||||
Participant Event Dial-in: | +1 (888) 506-0062 (North America) +1 (973) 528-0011 (International) | |||||
Participant Access Code: | 785090 | |||||
Replay Dial-in: | +1 (877) 481-4010 (North America) +1 (919) 882-2331 (International) | |||||
Replay Passcode: | 51712 (replay available until March 5, 2025) |
About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on X, LinkedIn, Facebook and Instagram.
© 2025 Bausch + Lomb.
| Last Trade: | US$12.06 |
| Daily Change: | 0.21 1.77 |
| Daily Volume: | 838,696 |
| Market Cap: | US$4.250B |
February 19, 2025 January 13, 2025 December 11, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
